Press Releases

Intensity Therapeutics Strengthens Intellectual Property Portfolio with Issuance of Several New Patents in Asia and Australia

Dec 11 2018

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune cell recognition of solid tumor cancers, today announced the receipt of patents protecting the Company’s technology and its lead product candidate, INT230-6, in China, Japan, Korea, Russia and Australia. All five countries have granted the Company a… Read more »

Intensity Therapeutics Highlights INT230-6 Data in Advanced Solid Tumors at Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

Nov 11 2018

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary immune cell-activating cancer treatments, today announced  additional data from a Phase 1/2 clinical study of INT230-6, the Company’s novel lead product candidate designed for direct intratumoral injection, and preclinical research highlighting the Company’s proprietary DfuseRxSM technology were presented in a poster session  at the Society for… Read more »

Intensity Therapeutics Raises $6.5 Million in Series B Financing

Nov 11 2018

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary immune cell-activating cancer treatments, today announced the completion of a $6.5 million Series B financing. Intensity plans to use the proceeds of the financing to advance the clinical development of lead product candidate INT230-6, a direct intratumoral injection that is currently being evaluated in a Phase… Read more »

View All Press Releases

Publications/Papers/Posters

SITC 2018 Poster Presentation P622

Phase 1/2 Evaluation of Intratumoral INT230-6 for the Treatment of Solid Tumors

ESMO 2018 Poster Presentation Abstract 4458

Phase 1/2 Evaluation of Intratumoral INT230-6 for the Treatment of Solid Tumors

ASCO 2018 Poster Presentation TPS2609

Phase 1/2 trial evaluating intratumoral administration of INT230-6 alone and in combination with an anti-PD1 antibody for advanced malignancies. TPS2609

View All Publications/Papers/Posters